Phase 2 N=115 Lipoic Acid for Progressive Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=280 A Phase 2b Study of Icosabutate in Fatty Liver Disease
Non Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Patients With Resolution of NASH, Defined as Disappearance of Ballooning (Score = 0) With Lobular Inflammation Score 0 or 1, With no Worsening of Fibrosis…
Phase 2 N=136 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000
Phase 2 N=56 An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
Dry Eye
Primary: Change From Baseline in Ocular Discomfort — 1.35; 2.07 score on a scale
Phase 2 N=7 Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
Microsatellite Stable · Mismatch Repair Protein Proficient · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Participants With Treatment-related, Dose-limiting Toxicities (DLT) (Safety Lead-In Cohort) — 0.33 proportion of participants
Phase 2 N=51 A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
Chronic Cough
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Phase 2 N=30 Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Mantle Cell Lymphoma
Primary: Single Agent Efficacy (as Determined by Response Rate) — 1; 2 Participants
Phase 2 N=64 Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Hematopoietic Cell Transplantation Recipient · Refractory B-Cell Non-Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Optimal Dose of Gemcitabine Hydrochloride Determined by Dose Limiting Toxicity — 0; 6; 20; 0 Participants
Phase 2 N=791 A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Chickenpox
Primary: Concentrations of Anti-varicella Zoster Virus (VZV) Glycoprotein E (gE) Antibodies — 960; 1071; 1555; 1284 mlU/ml
Phase 2 N=110 1% Chloroprocaine(PF) vs. Bupivacaine Spinals
Return of Motor and Sensory Blockade · Anesthesia, Spinal · Decrease Discharge Time Status Post Hemorrhoidectomy
Primary: Recovery Time — 134.1; 161.9 minutes
Phase 2 N=33 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants
Phase 2 N=26 A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
Ethanol Intoxication
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Phase 2 N=80 Race, Natriuretic Peptides and Physiological Perturbations
Healthy · Pre Hypertension
Primary: Change in Plasma BNP After 6-weeks of Beta-Blocker — 45; 74 Percentage Change in Plasma BNP levels
Phase 2 N=137 A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) · Chronic Bronchitis
Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic — 0.019; -0.005 Litre — p=0.216
Phase 2 N=43 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Amorphous, Eosinophilic, and Acellular Deposit · Constipation · Diarrhea
Primary: Assess Efficacy by Confirmed Overall Hematologic Response — 77.1 percentage of paticipants